Want to see JP:4521 full AI Analyst Report?
4521 Stock Chart & Stats
¥3890.00
¥0.00(0.00%)
At close: 4:00 PM EDT
¥3890.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥3,540.00 - ¥4,445.00
Previous CloseN/A
Volume70.00K
Average Volume (3M)164.95K
Market Cap
¥144.08B
Enterprise Value¥91.72K
Total Cash (Recent Filing)¥55.40B
Total Debt (Recent Filing)¥3.85B
Price to Earnings (P/E)14.7
Beta0.26
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.74%
Share Statistics
EPS (TTM)333.12
Shares Outstanding44,139,730
10 Day Avg. Volume176,660
30 Day Avg. Volume164,953
Financial Highlights & Ratios
PEG Ratio-0.87
Price to Book (P/B)1.06
Price to Sales (P/S)2.04
P/FCF Ratio-11.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)122.44
Revenue Forecast (FY)¥82.82B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a large equity base reduce refinancing risk and provide flexibility to sustain R&D, support commercialization, or absorb periods of weaker earnings without balance-sheet strain.
Specialty Pharmaceutical FocusA focused specialty portfolio and internal R&D platform can support differentiated products, specialized commercial expertise, and stronger customer relationships than a broadly undifferentiated drug portfolio.
Established Domestic Commercial ModelAn established prescription-drug platform gives Kaken access to recurring physician-led demand and Japan’s reimbursement system, while its salesforce and commercial operations support ongoing product monetization.
Bears Say
Sharp Revenue ContractionThe substantial revenue decline indicates pressure on product demand, lifecycle performance, or market conditions. Sustained contraction would weaken operating leverage and reduce the resources available for future pharmaceutical development.
Negative Cash GenerationA reversal to operating and free cash outflow raises earnings-quality and working-capital concerns. If cash generation does not normalize, internal funding for R&D, launches, and shareholder returns could become less flexible.
Profitability And ROE DeteriorationThe steep margin and return decline shows that the current product mix or cost base is not converting revenue efficiently. Persistently weak profitability would reduce the economic value of the company’s R&D and asset base.
Kaken Pharmaceutical Co News
4521 FAQ
What was Kaken Pharmaceutical Co Ltd’s price range in the past 12 months?
Kaken Pharmaceutical Co Ltd lowest stock price was ¥3540.00 and its highest was ¥4445.00 in the past 12 months.
What is Kaken Pharmaceutical Co Ltd’s market cap?
Kaken Pharmaceutical Co Ltd’s market cap is ¥144.08B.
When is Kaken Pharmaceutical Co Ltd’s upcoming earnings report date?
Kaken Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 05, 2026 which is in 76 days.
How were Kaken Pharmaceutical Co Ltd’s earnings last quarter?
Kaken Pharmaceutical Co Ltd released its earnings results on Aug 07, 2026. The company reported ¥222.86 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Kaken Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Kaken Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Kaken Pharmaceutical Co Ltd pay dividends?
Kaken Pharmaceutical Co Ltd pays a Semiannually dividend of ¥95 which represents an annual dividend yield of 4.74%. See more information on Kaken Pharmaceutical Co Ltd dividends here
What is Kaken Pharmaceutical Co Ltd’s EPS estimate?
Kaken Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kaken Pharmaceutical Co Ltd have?
Kaken Pharmaceutical Co Ltd has 44,139,730 shares outstanding.
What happened to Kaken Pharmaceutical Co Ltd’s price movement after its last earnings report?
Kaken Pharmaceutical Co Ltd reported an EPS of ¥222.86 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.961%.
Which hedge fund is a major shareholder of Kaken Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4521
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kaken Pharmaceutical Co Ltd
Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product portfolio includes specialized treatments like Clenafin, a topical solution for fungal nail infections; Artz, an agent combating osteoarthritis; Seprafilm, an absorbable film preventing surgical adhesions; Fiblast, a spray designed for pressure and skin ulcer healing; Regroth for periodontal tissue regeneration; and Hernicore, which addresses lumbar disc herniation. They also market Adofeed, a plaster for pain and inflammation relief; Ebrantil for dysuria and hypertension management; Procylin, an oral prostaglandin I2 analogue; Lipidil, used to treat high cholesterol; Mentax, an anti-fungal cream; and Loxoprofen Na Tape, another pain-relieving and anti-inflammatory patch. Additionally, Ropion is offered as an injectable pain medication. The company's agricultural and animal health division provides products such as Polyoxins, a fungicidal agent; Pentoxazone, a herbicide for rice crops; and Salinomycin, an anti-coccidial feed additive for poultry. Kaken Pharmaceutical is actively advancing several investigational compounds. BBI-4000 has completed its Phase III clinical trials for primary axillary hyperhidrosis, while KMW-1 is also in Phase III for managing eschar removal in thermal burns. KAR is being developed for hide lice infestation, and KP-607 is currently in Phase II for the treatment of onychomycosis. Beyond pharmaceuticals, the firm also manages the rental of the commercial property, Bunkyo Green Court. Its products are sold under various brand names, including Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia. The company holds licensing agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Established in 1917, Kaken Pharmaceutical Co., Ltd. has its main office situated in Tokyo, Japan.
Technical Analysis
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―



